PolyPid Ltd. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

PolyPid Ltd.'s Business Model

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About PolyPid Ltd.

Website: https://www.polypid.com

CEO (Chief Executive Officer): Ms. Dikla Czaczkes Akselbrad

IPO date: 2020-06-26

Contact

Country: IL

Address: 18 Hasivim Street

City: Petah Tikva

State: None

Phone: 972 7 4719 5700

Zip Code: 4959376

Other

CIK: 0001611842

ISIN: IL0011326795

CUSIP: M8001Q118

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.